布瑞那韦
临床资料 | |
---|---|
ATC码 |
|
识别信息 | |
| |
CAS号 | 313682-08-5 |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C33H41N3O10S2 |
摩尔质量 | 703.82 g·mol−1 |
3D模型(JSmol) | |
| |
|
布瑞那韦(INN:Brecanavir;开发代号:GW640385),或译作贝卡那韦、瑞卡那韦,是一种蛋白酶抑制剂,已被研究用于治疗艾滋病毒。[1]
2006年12月,其开发商葛兰素史克因配方方面存在难以克服的问题而停止了进一步的开发。[2]
参见
参考资料
- ^ Hazen R, Harvey R, Ferris R, et al. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob. Agents Chemother. September 2007, 51 (9): 3147–54. PMC 2043237 . PMID 17620375. doi:10.1128/AAC.00401-07.
- ^ GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385) (新闻稿). GlaxoSmithKline. 2006-12-18 [2008-06-11]. (原始内容存档于2008-12-03).